Adipokines in nonalcoholic steatohepatitis: From pathogenesis to implications in diagnosis and therapy

Mediators of Inflammation

Volumn 2009, Issue , 2009, Pages

  Tsochatzis, Emmanuel A ^a   Papatheodoridis, George V ^a   Archimandritis, Athanasios J ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CYTOKINE; INFLIXIMAB; INTERLEUKIN 6; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PENTOXIFYLLINE; PIOGLITAZONE; RESISTIN; RETINOL BINDING PROTEIN 4; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; ADIPONECTIN, HUMAN; RETN PROTEIN, HUMAN;

ADIPOSE TISSUE; CLINICAL FEATURE; CLINICAL PRACTICE; CYTOKINE RELEASE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; EXPERIMENTAL ANIMAL; GASTROINTESTINAL SYMPTOM; HUMAN; LIPID STORAGE; LIVER FIBROSIS; LIVER NECROSIS; METABOLIC SYNDROME X; NAUSEA; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; DRUG ANTAGONISM; FATTY LIVER; PHYSIOLOGY;

ADIPOKINES; ADIPONECTIN; FATTY LIVER; HUMANS; INTERLEUKIN-6; LEPTIN; RESISTIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70449706044     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2009/831670     Document Type: Review

References (98)

1. G. Marchesini, E. Bugianesi, G. Forlani, et al., "Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome, " Hepatology, vol. 37, no. 4, pp. 917-923, 2003.
2. E. Tsochatzis, G. V. Papatheodoridis, E. K. Manesis, G. Kafiri, D. G. Tiniakos, and A. J. Archimandritis, "Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis, " Alimentary Pharmacology and Therapeutics, vol. 27, no. 1, pp. 80-89, 2008.
3. E. A. Tsochatzis, S. Manolakopoulos, G. V. Papatheodoridis, and A. J. Archimandritis, "Insulin resistance and metabolic syndrome in chronic liver diseases: old entities with new implications, " Scandinavian Journal of Gastroenterology, vol. 44, no. 1, pp. 6-14, 2009.
4. S. Bellentani, G. Saccoccio, F. Masutti, et al., "Prevalence of and risk factors for hepatic steatosis in Northern Italy, " Annals of Internal Medicine, vol. 132, no. 2, pp. 112-117, 2000.
5. J. D. Browning, L. S. Szczepaniak, R. Dobbins, et al., "Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity, " Hepatology, vol.40, no.6, pp. 1387-1395, 2004.
6. G. V. Papatheodoridis, J. Goulis, D. Christodoulou, et al., "High prevalence of elevated liver enzymes in blood donors: associations with male gender and central adiposity, " European Journal of Gastroenterology & Hepatology, vol.19, no.4, pp. 281-287, 2007.
7. G. C. Farrell and C. Z. Larter, "Nonalcoholic fatty liver disease: from steatosis to cirrhosis, " Hepatology, vol. 43, no. 2, supplement 1, pp. S99-S112, 2006.
8. C. P. Day and O. F. W. James, "Steatohepatitis: a tale of two "hits"?" Gastroenterology, vol. 114, no. 4, pp. 842-845, 1998.
9. L.A.Adams, J.F.Lymp, J.St.Sauver, etal., "Thenatural history of nonalcoholic fatty liver disease: a population-based cohort study, " Gastroenterology, vol. 129, no. 1, pp. 113-121, 2005.
10. M. Ekstedt, L. E. Franzén, U. L. Mathiesen, et al., "Long- term follow-up of patients with NAFLD and elevated liver enzymes, " Hepatology, vol. 44, no. 4, pp. 865-873, 2006.
11. A. Wieckowska, A. J. McCullough, and A. E. Feldstein, "Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future, " Hepatology, vol. 46, no. 2, pp. 582-589, 2007.
12. E. Tsochatzis, G. V. Papatheodoridis, and A. J. Archimandritis, "The evolving role of leptin and adiponectin in chronic liver diseases, " The American Journal of Gastroenterology, vol. 101, no. 11, pp. 2629-2640, 2006.
13. A. S. Greenberg and M. S. Obin, "Obesity and the role of adipose tissue in inflammation and metabolism, " American Journal of Clinical Nutrition, vol. 83, no. 2, pp. 461S-465S, 2006.
14. Y. Kamada, T. Takehara, and N. Hayashi, "Adipocytokines and liver disease, " Journal of Gastroenterology, vol. 43, no. 11, pp. 811-822, 2008.
15. R. N. Bergman, "New concepts in extracellular signaling for insulin action: the single gateway hypothesis, " Recent Progress in Hormone Research, vol. 52, pp. 359-385, 1997.
16. E. Bugianesi, A. J. McCullough, and G. Marchesini, "Insulin resistance: a metabolic pathway to chronic liver disease, " Hepatology, vol. 42, no. 5, pp. 987-1000, 2005.
17. P. Angulo, "Nonalcoholic fatty liver disease, " The New England Journal of Medicine, vol. 346, no. 16, pp. 1221-1231, 2002.
18. D. Pessayre and B. Fromenty, "NASH: a mitochondrial disease, " Journal of Hepatology, vol. 42, no. 6, pp. 928-940, 2005.
19. M. Curzio, H. Esterbauer, G. Poli, et al., "Possible role of aldehydic lipid peroxidation products as chemoattractants, " International Journal of Tissue Reactions, vol. 9, no. 4, pp. 295-306, 1987.
20. H. Hug, S. Strand, A. Grambihler, et al., "Reactive oxygen intermediates are involved in the induction of CD95 ligand mRNA expression by cytostatic drugs in hepatoma cells, " The Journal of Biological Chemistry, vol. 272, no. 45, pp. 28191-28193, 1997.
21. G. Leonarduzzi, A. Scavazza, F. Biasi, et al., "The lipid peroxidation end product 4-hydroxy-2, 3-nonenal up- regulates transforming growth factor beta1 expression in the macrophage lineage: a link between oxidative injury and fibrosclerosis, " The FASEB Journal, vol. 11, no. 11, pp. 851-857, 1997.
22. I. R. Wanless and K. Shiota, "The pathogenesis ofnonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis, " Seminars in Liver Disease, vol. 24, no. 1, pp. 99-106, 2004.
23. Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold, and J. M. Friedman, "Positional cloning of the mouse obese gene and its human homologue, " Nature, vol. 372, no. 6505, pp. 425-432, 1994.
24. C. S. Mantzoros, "The role of leptin in human obesity and disease: a review of current evidence, " Annals of Internal Medicine, vol. 130, no. 8, pp. 671-680, 1999.
25. R. H. Unger, "Lipotoxic diseases, " Annual Review of Medicine, vol. 53, pp. 319-336, 2002.
26. T. Kakuma, Y. Lee, M. Higa, et al., "Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets, " Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 15, pp. 8536-8541, 2000.
27. K. Ikejima, H. Honda, M. Yoshikawa, et al., "Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals, " Hepatology, vol. 34, no. 2, pp. 288-297, 2001.
28. F. Marra, "Leptin and liver fibrosis: a matter of fat, " Gastroenterology, vol. 122, no. 5, pp. 1529-1532, 2002.
29. K. Ikejima, Y. Takei, H. Honda, et al., "Leptin receptor- mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat, " Gastroenterology, vol. 122, no. 5, pp. 1399-1410, 2002.
30. N. K. Saxena, K. Ikeda, D. C. Rockey, S. L. Friedman, and F. A. Anania, "Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice, " Hepatology, vol. 35, no. 4, pp. 762-771, 2002.
31. U. B. Pajvani, X. Du, T. P. Combs, et al., "Structure- function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity, " The Journal ofBiological Chemistry, vol. 278, no. 11, pp. 9073-9085, 2003.
32. J. Beitowski, "Adiponectin and resistin-new hormones of white adipose tissue, " Medical Science Monitor, vol. 9, no. 2, pp. RA55-RA61, 2003.
33. F. A. Anania, "Adiponectin and alcoholic fatty liver: is it, after all, about what you eat?" Hepatology, vol. 42, no. 3, pp. 530-532, 2005.
34. M. You, R. V. Considine, T. C. Leone, D. P. Kelly, and D. W. Crabb, "Role ofadiponectin in the protective action ofdietary saturated fat against alcoholic fatty liver in mice, " Hepatology, vol. 42, no. 3, pp. 568-577, 2005.
35. S. Shklyaev, G. Aslanidi, M. Tennant, et al., "Sustained peripheral expression of transgene adiponectin offsets the development of diet-induced obesity in rats, " Proceedings of the National Academy ofSciences ofthe United States ofAmerica, vol. 100, no. 24, pp. 14217-14222, 2003.
36. Y. Kamada, H. Matsumoto, S. Tamura, et al., "Hypoad- iponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model, " Journal ofHepatology, vol. 47, no. 4, pp. 556-564, 2007.
37. T. Masaki, S. Chiba, H. Tatsukawa, et al., "Adiponectin protects LPS-induced liver injury through modulation of TNF-a in KK-Ay obese mice, " Hepatology, vol. 40, no. 1, pp. 177-184, 2004.
38. A. Xu, Y. Wang, H. Keshaw, L. Y. Xu, K. S. L. Lam, and G.J. S. Cooper, "The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice, " The Journal ofClinical Investigation, vol. 112, no. 1, pp. 91-100, 2003.
39. K. Tomita, Y. Oike, T. Teratani, et al., "Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice, " Hepatology, vol. 48, no. 2, pp. 458-473, 2008.
40. G. S. Hotamisligil, N. S. Shargill, and B. M. Spiegelman, "Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance, " Science, vol. 259, no. 5091, pp. 87-91, 1993.
41. K. E. Wellen and G. S. Hotamisligil, "Obesity-induced inflammatory changes in adipose tissue, " The Journal of Clinical Investigation, vol. 112, no. 12, pp. 1785-1788, 2003.
42. L. Valenti, A. L. Fracanzani, P. Dongiovanni, et al., "Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease, " Gastroenterology, vol. 122, no. 2, pp. 274-280, 2002.
43. K. Tokushige, M. Takakura, N. Tsuchiya-Matsushita, M. Taniai, E. Hashimoto, and K. Shiratori, "Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis, " JournalofHepatology, vol. 46, no.6, pp. 1104-1110, 2007.
44. J. Poniachik, A. Csendes, J. C. Díaz, et al., "Increased production of IL- 1α and TNF-α in lipopolysaccharide-stimulated blood from obese patients with non-alcoholic fatty liver disease, " Cytokine, vol. 33, no. 5, pp. 252-257, 2006.
45. A. E. Feldstein, N. W. Werneburg, A. Canbay, et al., "Free fatty acids promote hepatic lipotoxicity by stimulating TNF- α expression via a lysosomal pathway, " Hepatology, vol. 40, no. 1, pp. 185-194, 2004.
46. K. Tomita, G. Tamiya, S. Ando, et al., "Tumour necrosis factor a signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice, " Gut, vol. 55, no. 3, pp. 415-424, 2006.
47. Z. Li, S. Yang, H. Lin, et al., "Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease, " Hepatology, vol. 37, no. 2, pp. 343-350, 2003.
48. L. Patel, A. C. Buckels, I. J. Kinghorn, et al., "Resistin is expressed in human macrophages and directly regulated by PPARy activators, " Biochemical and Biophysical Research Communications, vol. 300, no. 2, pp. 472-476, 2003.
49. M. Pravenec, L. Kazdová, V. Landa, et al., "Transgenic and recombinant resistin impair skeletal muscle glucose metabolism in the spontaneously hypertensive rat, " The Journal ofBiological Chemistry, vol. 278, no. 46, pp. 45209-45215, 2003.
50. M. W. Rajala, S. Obici, P. E. Scherer, and L. Rossetti, "Adipose- derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production, " The Journal ofClinical Investigation, vol. 111, no. 2, pp. 225-230, 2003.
51. S. M. Rangwala, A. S. Rich, B. Rhoades, et al., "Abnormal glucose homeostasis due to chronic hyperresistinemia, " Diabetes, vol. 53, no. 8, pp. 1937-1941, 2004.
52. H. Satoh, M. T. A. Nguyen, P. D. G. Miles, T. Imamura, I. Usui, and J. M. Olefsky, "Adenovirus-mediated chronic "hyper- resistinemia" leads to in vivo insulin resistance in normal rats, " The Journal ofClinical Investigation, vol. 114, no. 2, pp. 224-231, 2004.
53. R. Palanivel and G. Sweeney, "Regulation of fatty acid uptake and metabolism in L6 skeletal muscle cells by resistin, " FEBS Letters, vol. 579, no. 22, pp. 5049-5054, 2005.
54. C. M. Steppan, J. Wang, E. L. Whiteman, M. J. Birnbaum, and M. A. Lazar, "Activation of SOCS-3 by resistin, " Molecular and Cellular Biology, vol. 25, no. 4, pp. 1569-1575, 2005.
55. N. Silswal, A. K. Singh, B. Aruna, S. Mukhopadhyay, S. Ghosh, and N. Z. Ehtesham, "Human resistin stimulates the pro- inflammatory cytokines TNF-a and IL-12 in macrophages by NF-jcB-dependent pathway, " Biochemical and Biophysical Research Communications, vol. 334, no. 4, pp. 1092-1101, 2005.
56. M. Bokarewa, I. Nagaev, L. Dahlberg, U. Smith, and A. Tarkowski, " Resistin, an adipokine with potent proinflamma- tory properties, " The Journal of Immunology, vol. 174, no. 9, pp. 5789-5795, 2005.
57. C. Bertolani, P. Sancho-Bru, P. Failli, et al., "Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells, " American Journal of Pathology, vol. 169, no. 6, pp. 2042-2053, 2006.
58. D. E. Cressman, L. E. Greenbaum, R. A. DeAngelis, et al., "Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice, " Science, vol. 274, no. 5291, pp. 1379-1383, 1996.
59. O. El-Assal, F. Hong, W.H.Kim, S.Radaeva, and B. Gao, "IL- 6-deficient mice are susceptible to ethanol-induced hepatic steatosis: IL-6 protects against ethanol-induced oxidative stress and mitochondrial permeability transition in the liver, " Cellular & Molecular Immunology, vol. 1, no. 3, pp. 205-211, 2004.
60. N. Teoh, J. Field, and G. Farrell, "Interleukin-6 is a key mediator of the hepatoprotective and pro-proliferative effects of ischaemic preconditioning in mice, " Journal of Hepatology, vol. 45, no. 1, pp. 20-27, 2006.
61. A. Blindenbacher, X. Wang, I. Langer, R. Savino, L. Ter- racciano, and M. H. Heim, "Interleukin 6 is important for survival after partial hepatectomy in mice, " Hepatology, vol. 38, no. 3, pp. 674-682, 2003.
62. X. Jin, T. A. Zimmers, E. A. Perez, R. H. Pierce, Z. Zhang, and L. G. Koniaris, "Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair, " Hepatology, vol. 43, no. 3, pp. 474-484, 2006.
63. Q. Yang, T. E. Graham, N. Mody, et al., "Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes, " Nature, vol. 436, no. 7049, pp. 356-362, 2005.
64. T. E. Graham, Q. Yang, M. Blüher, et al., "Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects, " The New England Journal of Medicine, vol. 354, no. 24, pp. 2552-2563, 2006.
65. N. Klöting, T. E. Graham, J. Berndt, et al., "Serum retinol- binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra- abdominal fat mass, " Cell Metabolism, vol. 6, no. 1, pp. 79-87, 2007.
66. P. Balagopal, T. E. Graham, B. B. Kahn, A. Altomare, V. Funan- age, and D. George, "Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation, " The Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 5, pp. 1971-1974, 2007.
67. A. Yao-Borengasser, V. Varma, A. M. Bodles, et al., "Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglita- zone, " The Journal ofClinical Endocrinology& Metabolism, vol. 92, no. 7, pp. 2590-2597, 2007.
68. A. Fukuhara, M. Matsuda, M. Nishizawa, et al., "Visfatin: a protein secreted by visceral fat that Mimics the effects of insulin, " Science, vol. 307, no. 5708, pp. 426-430, 2005. (Pubitemid 40139988)
69. S. Chitturi, G. Farrell, L. Frost, et al., "Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity?" Hepatology, vol.36, no.2, pp. 403-409, 2002.
70. P. Angulo, L.M.Alba, L.M.Petrovic, L. A. Adams, K. D. Lindor, and M. D. Jensen, "Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease, " Journal of Hepatology, vol. 41, no. 6, pp. 943-949, 2004.
71. N. Chalasani, D. W. Crabb, O. W. Cummings, et al., "Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis?" The American Journal of Gastroenterology, vol. 98, no. 12, pp. 2771-2776, 2003.
72. G. Musso, R. Gambino, M. Durazzo, et al., "Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease, " Hepatology, vol.42, no.5, pp. 1175-1183, 2005.
73. E. Tsochatzis, G. V. Papatheodoridis, E. Hadziyannis, et al., "Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity, " Scandinavian Journal of Gastroenterology, vol. 43, no. 9, pp. 1128-1136, 2008.
74. A. Uygun, A. Kadayifci, Z. Yesilova, et al., "Serum leptin levels in patients with nonalcoholic steatohepatitis, " The American Journal of Gastroenterology, vol. 95, no. 12, pp. 3584-3589, 2000.
75. E. Bugianesi, U. Pagotto, R. Manini, et al., "Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity, " The Journal ofClinical Endocrinology & Metabolism, vol. 90, no. 6, pp. 3498-3504, 2005.
76. J. M. Hui, A. Hodge, G. C. Farrell, J. G. Kench, A. Kriketos, and J. George, "Beyond insulin resistance in NASH: TNF-a or adiponectin?" Hepatology, vol. 40, no. 1, pp. 46-54, 2004.
77. M. Shimada, H. Kawahara, K. Ozaki, et al., "Usefulness of a combined evaluation of the serum adiponectin level, HOMA- IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis, " The American Journal of Gastroenterology, vol. 102, no. 9, pp. 1931-1938, 2007.
78. Z. M. Younossi, M. Jarrar, C. Nugent, et al., "A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH), " Obesity Surgery, vol. 18, no. 11, pp. 1430-1437, 2008.
79. A. Y.-H. Wang, I. J. Hickman, A. A. Richards, J. P. Whitehead, J. B. Prins, and G. A. MacDonald, "High molecular weight adiponectin correlates with insulin sensitivity in patients with hepatitis C genotype 3, but not genotype 1 infection, " The American Journal of Gastroenterology, vol. 100, no. 12, pp. 2717-2723, 2005.
80. M. Nannipieri, F. Cecchetti, M. Anselmino, et al., "Pattern of expression of adiponectin receptors in human liver and its relation to nonalcoholic steatohepatitis, " Obesity Surgery, vol. 19, no. 4, pp. 467-474, 2009.
81. H. Ma, V. Gomez, L. Lu, X. Yang, X. Wu, and S.-Y. Xiao, "Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease, " Journal of Gastroenterology and Hepatology, vol. 24, no. 2, pp. 233-237, 2009.
82. S. Kaser, A. Maschen, A. Cayon, et al., "Adiponectin and its receptors in non-alcoholic steatohepatitis, " Gut, vol. 54, no. 1, pp. 117-121, 2005. (Pubitemid 40007229)
83. G. Musso, R. Gambino, F. De Michieli, M. Durazzo, G. Pagano, and M. Cassader, "Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: possible pathogenetic role in NASH, " Hepatology, vol. 47, no. 4, pp. 1167-1177, 2008.
84. S. Abiru, K. Migita, Y. Maeda, et al., "Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis, " Liver International, vol. 26, no. 1, pp. 39-45, 2006.
85. V. W. Wong, A. Y. Hui, S. W. Tsang, et al., "Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease, " Clinical Gastroenterology and Hepatology, vol. 4, no. 9, pp. 1154-1161, 2006.
86. M. H. Jarrar, A. Baranova, R. Collantes, et al., "Adipokines and cytokines in non-alcoholic fatty liver disease, " Alimentary Pharmacology and Therapeutics, vol. 27, no. 5, pp. 412-421, 2008.
87. C. Pagano, G. Soardo, C. Pilon, et al., "Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance, " The Journal ofClinical Endocrinology & Metabolism, vol. 91, no. 3, pp. 1081-1086, 2006.
88. A. Wieckowska, B. G. Papouchado, Z. Li, R. Lopez, N. N. Zein, and A. E. Feldstein, "Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis, " The American Journal ofGastroenterology, vol. 103, no. 6, pp. 1372-1379, 2008.
89. D. García-Galiano, M. A. Sáunchez-Garrido, I. Espejo, et al., "IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients, " Obesity Surgery, vol. 17, no. 4, pp. 493-503, 2007.
90. J. W. Haukeland, J. K. Damås, Z. Konopski, et al., "Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels ofCCL2, " Journal ofHepatology, vol. 44, no. 6, pp. 1167-1174, 2006.
91. J. A. Seo, N. H. Kim, S. Y. Park, et al., "Serum retinol- binding protein 4 levels are elevated in non-alcoholic fattyliver disease, " Clinical Endocrinology, vol. 68, no. 4, pp. 555-560, 2008.
92. R. Aller, D. A. de Luis, O. Izaola, et al., "Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease, " to appear in Digestive Diseases and Sciences.
93. L. A. Adams, C. O. Zein, P. Angulo, and K. D. Lindor, "A pilot trial of pentoxifylline in nonalcoholic steatohepatitis, " The American Journal of Gastroenterology, vol. 99, no. 12, pp. 2365-2368, 2004.
94. S. K. Satapathy, P. Sakhuja, V. Malhotra, B. C. Sharma, and S. K. Sarin, "Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis, " Journal of Gastroenterology and Hepatology, vol. 22, no. 5, pp. 634-638, 2007.
95. S. S. Koca, I. H. Bahcecioglu, O. K. Poyrazoglu, I. H. Ozercan, K. Sahin, and B. Ustundag, "The treatment with antibody of TNF-α reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet, " Inflammation, vol. 31, no. 2, pp. 91-98, 2008.
96. S. Naveau, S. Chollet-Martin, S. Dharancy, et al., "A double- blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis, " Hepatology, vol. 39, no. 5, pp. 1390-1397, 2004.
97. R. Belfort, S. A. Harrison, K. Brown, et al., "A placebo- controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis, " The New England Journal ofMedicine, vol. 355, no. 22, pp. 2297-2307, 2006.
98. J. S. Smolen, A. Beaulieu, A. Rubbert-Roth, et al., "Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial, " The Lancet, vol. 371, no. 9617, pp. 987-997, 2008.